In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on aTyr Pharma, with a price target of $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors surrounding aTyr Pharma’s promising developments and financial standing. The company has recently completed the last patient visit in its pivotal Phase 3 EFZO-FIT trial with efzofitimod for pulmonary sarcoidosis, with topline data expected in mid-September 2025. This milestone, along with the interim update from the Phase 2 EFZO-CONNECT trial for systemic sclerosis-related ILD, indicates significant progress in their clinical pipeline.
Additionally, aTyr Pharma’s financial health supports this optimistic outlook. With approximately $83.2 million in cash and cash equivalents as of June 30, 2025, and an additional $30.7 million raised from an at-the-market offering, the company has a cash runway expected to last into the third quarter of 2026. The valuation of aTyr Pharma, based on a combination of discounted cash flow, net present value, and price-to-earnings ratios, suggests a price target of $22 per share, reflecting the potential for substantial growth driven by their innovative treatments.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.